RABEPRAZOLE SODIUM | A076822 | TEVA PHARMACEUTICALS USA INC
Total Spending
$15.3M
Total Claims
233,700
Beneficiaries
65,972
Avg Cost/Unit
$0.79
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.
13 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Nov 13, 2013 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.